Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
237 Leser
Artikel bewerten:
(1)

MMJ International Holdings: DEA BUSTED!! While Chinese Marijuana Cartels Spread Right Under DEA's Nose, FDA CANNABIS RESEARCH BLOCKED

While Chinese cartels built a marijuana empire across at least six states, MMJ-a Rhode Island-based company with FDA orphan drug status-was left to rot in a bureaucratic black hole engineered by DEA Diversion officials Matthew Strait, Thomas Prevoznik, Anne Milgram and Aarathi Haig.

WASHINGTON, D.C. / ACCESS Newswire / July 1, 2025 / Just nine days after MMJ BioPharma Cultivation publicly exposed the DEA's failure to act on sprawling Chinese-backed illegal marijuana grows, the agency finally made headlines launching raids on massive criminal cannabis operations in Oklahoma tied to Chinese nationals. The bust involved over 40,000 plants, firearms, and cartel-style logistics.

But this long-overdue enforcement action raises a disturbing question:

Why has the DEA prioritized foreign crime syndicates only after years of silence and why is it still blocking a federally-compliant company like MMJ from advancing FDA authorized medical research?

DEA Ignored Foreign Criminal Networks Until Publicly Shamed
MMJ BioPharma Cultivation warned of DEA inaction over CCP linked marijuana grows on June 18, 2025. Just nine days later, the DEA moved in Oklahoma raiding what officials described as one of the largest criminal marijuana networks in U.S. history. The target: a Chinese syndicate with ties to the United Front Work Department (UFWD), the CCP's global influence arm.

"DEA had time to delay a law-abiding FDA-regulated company, but no time to shut down transnational farms tied to COMMUNIST CHINESE PARTY front groups. That's not just negligence; it's national security malpractice."
- Duane Boise, CEO, MMJ BioPharma Cultivation

While Chinese cartels built a marijuana empire across at least six states, MMJ, a Rhode Island-based company with FDA orphan drug status, was left to rot in a bureaucratic black hole engineered by DEA Diversion officials Matthew Strait, Thomas Prevoznik, Anne Milgram, and Aarathi Haig.

Science Stifled, Crime Rewarded
For over 2,390 days, MMJ has complied with every federal requirement to grow marijuana for clinical trials targeting Huntington's Disease and Multiple Sclerosis. But instead of supporting medical innovation, the DEA:

  • Ignored timelines under its own regulations

  • Forced MMJ into unconstitutional ALJ proceedings

  • Withheld a valid Order to Show Cause remedy

  • Allowed foreign criminal groups to operate unimpeded in the meantime

Worse, while MMJ was stalled, Strait and Prevoznik were sent to Dubai on taxpayer money to pose as drug policy "experts."

Supreme Court: DEA's Legal System Was Illegal
In a pair of landmark rulings, Axon v. FTC and Jarkesy v. SEC, the U.S. Supreme Court deemed the DEA's in-house judge system unconstitutional. These were the very proceedings used to sabotage MMJ's progress.

The Department of Justice has since abandoned the defense of these cases, leaving DEA Diversion leadership exposed for systemic abuse of power.

Florida Hemp Stats Show DEA Failure
A study by the Florida Department of Agriculture found:

  • 64% of hemp-derived products were actually illegal marijuana

  • 44% contained toxic pesticides

  • DEA enforcement? Zero.

Meanwhile, lab-made THC analogs like Delta-8, HHC, and THC-A are sold on every street corner without oversight, while MMJ's tightly controlled FDA pathway remains blocked.

DEA Must Now Face the Real Questions
With Matthew Strait quietly retiring under a cloud of scandal and Anne Milgram already gone, pressure mounts on Deputy Administrator Thomas Prevoznik, the architect of the cannabis blockade.

Incoming DEA Administrator Terrance Cole has a moment of reckoning:

Will he fix the agency or protect its worst actors?

MMJ and the Path Forward
If the DEA truly wants to reclaim its credibility, it must:

  1. Immediately approve MMJ's registration

  2. Audit Diversion Control Division corruption

  3. End all ALJ hearings on cannabis licensing

  4. Transfer cannabis oversight to FDA/NIH

  5. Prosecute-not promote-DEA staff who obstructed medical research

Final Word
The DEA's sudden action on Chinese organized crime proves one thing: they can act when the pressure is real. MMJ's warnings, backed by years of compliance and legal action, helped trigger a long-overdue enforcement response.

But busting Chinese gangs isn't enough. It's time the DEA stops being the enemy of American science.

Until MMJ BioPharma Cultivation gets the registration it lawfully earned, and patients gain access to cannabinoid therapies they desperately need, the DEA's War on Medical Cannabis continues.

MMJ is represented by attorney Megan Sheehan.

CONTACT:
Madison Hisey
mhisey@mmjih.com
203-231-8583

SOURCE: MMJ International Holdings



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/dea-busted-while-chinese-marijuana-cartels-spread-right-under-deas-no-1044296

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.